Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Jianhua Shi et al.|The Lancet Respiratory Medicine|2020Cited by 504
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 311
Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Mengzhao Wang, Xia Song et al.|Thoracic Cancer|2019Cited by 26
Molecular analysis of cell‐free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancerJie Zhang, Henghui Zhang, Chen Tian et al.|Cancer Communications|2019Cited by 11